Vestibular schwannomas (VS) are benign tumors originating from the Schwann cells that form the myelin sheath of the cochleovestibular nerve .They can be classified into two groups: sporadic VS (90-95% of cases) and those associated to neurofibromatosis type 2 syndrome (NF2) (5-10% of cases). VS grow slowly and cause hearing loss both due to compression of the auditory nerve and the release of ototoxic substances. Currently, patients undergo periodic MRI, surgery, gamma-radiosurgery or radiotherapy as tumor treatment but there are no pharmacological approved therapies to treat these tumors. Here we explore a two-hit combination therapy for VS based on the induction of cellular senescence in the NF2-VS cell line HEI-193 by DNA damage stress (DDS) signals and the subsequent activation of apoptosis on these cells by treatment with senolytic drug.

Trabajo presentado en el 44º Congreso Nacional de la Sociedad Española de Bioquímica y Biología Molecular (SEBBM), celebrado en Málaga (España) del 06 al 09 de septiembre de 2022.